We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




RNAs Are Altered in Melanoma

By LabMedica International staff writers
Posted on 26 May 2011
A long, noncoding (lnc) RNA is elevated in melanoma cells, where it promotes cellular survival and invasion.

Scientists have discovered that levels of a relatively understudied group of RNAs–long, non-coding RNAs (lncRNAs)–are altered in human melanoma. More...
Dr. Ranjan Perera, associate professor at Sanford-Burnham Medical Research Institute (Sanford-Burnham; Orlando, FL, USA), and collaborators at the University of Queensland (Brisbane, Australia) compared lncRNAs in several laboratory cell-lines of melanoma and normal skin cells, as well as in 30 different human patient samples. They found that levels of the lncRNA, SPRY4-IT1, were particularly high in melanoma cells, but not in normal skin cells.

The study, published online May 10, 2011, in the journal Cancer Research showed that the elevated levels of SPRY4-IT1 in melanoma cells, promoted cellular survival and invasion.

To further probe the function of this lncRNA, they looked at what happens in a melanoma cell-line where SPRY4-IT1 levels are significantly reduced. Cellular growth was impaired and cell death was increased in the SPRY4-IT1-deficient melanoma cells, as compared to melanoma cells with fully functioning lncRNAs. In addition, the ability of melanoma cells to invade the extracellular matrix (an early step in cancer cell metastasis) was reduced in cells lacking SPRY4-IT1.

"The elevated expression of SPRY4-IT1 in melanoma cells, its accumulation in the cell cytoplasm, and effects on cell dynamics all suggest that increased SPRY4-IT1 may play an important role in the molecular underpinnings of human melanoma," said Prof. Perera. "Based on this information, we believe SPRY4-IT1 could be an early biomarker for the detection of melanoma."

In a separate study published in the journal PLoS ONE, in November 2010, Dr. Perera's group reported that melanoma cells have lower levels of a different non-coding RNA, called miR-211. Together, these two studies give scientists a better understanding of melanoma development, which in turn will help them design new diagnostics and therapeutics for this often-fatal disease.

Related Links:

Burnham Medical Research Institute
University of Queensland



New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
Pipette
Accumax Smart Series
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.